Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩1,034,000.00
Day range
₩1,015,000.00 - ₩1,040,000.00
Year range
₩722,000.00 - ₩1,209,000.00
Market cap
72.53T KRW
Avg Volume
80.03K
P/E ratio
56.68
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 1.30T | 37.11% |
Operating expense | 241.41B | 22.51% |
Net income | 375.55B | 109.38% |
Net profit margin | 28.93 | 52.75% |
Earnings per share | 5.28K | 109.40% |
EBITDA | 650.09B | 78.25% |
Effective tax rate | 24.80% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.29T | -37.61% |
Total assets | 17.44T | 5.53% |
Total liabilities | 6.16T | -5.47% |
Total equity | 11.28T | — |
Shares outstanding | 71.17M | — |
Price to book | 6.52 | — |
Return on assets | 7.00% | — |
Return on capital | 9.70% | — |
Cash Flow
Net change in cash
| (KRW) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 375.55B | 109.38% |
Cash from operations | 682.98B | 135.64% |
Cash from investing | -250.22B | -142.78% |
Cash from financing | -69.80B | 65.49% |
Net change in cash | 360.84B | -47.87% |
Free cash flow | -103.14B | -115.61% |
About
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Founded
2011
Website
Employees
4,770
